At the request of the pharmaceutical industry, FDA is modifying the questions subjects will be asked in a study to assess the impact of limiting the risk information presented in direct-to-consumer television ads to risks that are “serious and actionable.”
However, despite concerns raised by the Pharmaceutical Research and Manufacturers of America, the agency will use modified versions of existing...